Seelos Therapeutics is a responsibly-driven brand that is dedicated to addressing the significant unmet needs in CNS disorders and rare diseases. They are committed to developing innovative products that efficiently target these conditions. With a focus on delivering impactful solutions, Seelos Therapeutics aims to improve the lives of individuals and families affected by these disorders.

Their pipeline includes a range of promising products such as SLS-002 (intranasal ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD), SLS-003 (sublingual ketamine), SLS-004 (gene therapy), SLS-005 (trehalose), and SLS-007 (peptidic inhibitor). Seelos Therapeutics also actively supports patients and caregivers, providing information and resources. They are involved in important clinical trials and initiatives like the STRIDES-SCA HEALEY ALS Platform Trial – Regimen E and a study of SLS-002 in adults with Major Depressive Disorder at imminent risk of suicide.

Investors and media can find comprehensive information about Seelos Therapeutics, including financials, corporate governance, press releases, and SEC filings. Headquartered in New York, Seelos Therapeutics is driven by a passionate team dedicated to making a positive impact in the field of healthcare